Loading company
Loading
Open Financials NRX Pharmaceuticals, Inc. (NRXP) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $1.2 million | $0 | 10-K 2026-03-23 · proof | |
| Gross profit | $720,000 | $0 | 10-K 2026-03-23 · proof | |
| Operating income | -$16.2 million | -$18.5 million | 10-K 2026-03-23 · proof | |
| Net income | -$28.6 million | -$25.1 million | 10-K 2026-03-23 · proof | |
| Cash from operating activities | -$14.1 million | -$10.6 million | 10-K 2026-03-23 · proof | |
| Total assets | $13 million | $3.7 million | +254.9% | 10-K 2026-03-23 · proof |
| Total liabilities | $28.9 million | $26.9 million | +7.5% | 10-K 2026-03-23 · proof |
| Cash and cash equivalents | $7.8 million | $1.4 million | +440.3% | 10-K 2026-03-23 · proof |
- What was NRX Pharmaceuticals, Inc. (NRXP)'s revenue in fiscal 2025?
- NRX Pharmaceuticals, Inc. (NRXP) reported revenue of $1.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $0 the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
- What was NRX Pharmaceuticals, Inc. (NRXP)'s gross profit in fiscal 2025?
- NRX Pharmaceuticals, Inc. (NRXP) reported gross profit of $720,000 for fiscal 2025 (the year ended Dec 31, 2025), against $0 the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
- What was NRX Pharmaceuticals, Inc. (NRXP)'s operating income in fiscal 2025?
- NRX Pharmaceuticals, Inc. (NRXP) reported operating income of -$16.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$18.5 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
- What was NRX Pharmaceuticals, Inc. (NRXP)'s net income in fiscal 2025?
- NRX Pharmaceuticals, Inc. (NRXP) reported net income of -$28.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$25.1 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
- What was NRX Pharmaceuticals, Inc. (NRXP)'s cash from operating activities in fiscal 2025?
- NRX Pharmaceuticals, Inc. (NRXP) reported cash from operating activities of -$14.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$10.6 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
- What are NRX Pharmaceuticals, Inc. (NRXP)'s total assets?
- As of Dec 31, 2025, NRX Pharmaceuticals, Inc. (NRXP) reported total assets of $13 million, against $3.7 million a year earlier (+254.9%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
- What are NRX Pharmaceuticals, Inc. (NRXP)'s total liabilities?
- As of Dec 31, 2025, NRX Pharmaceuticals, Inc. (NRXP) reported total liabilities of $28.9 million, against $26.9 million a year earlier (+7.5%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
- What are NRX Pharmaceuticals, Inc. (NRXP)'s cash and cash equivalents?
- As of Dec 31, 2025, NRX Pharmaceuticals, Inc. (NRXP) reported cash and cash equivalents of $7.8 million, against $1.4 million a year earlier (+440.3%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:NRXP&period_type=annual&limit=5"Information only, not investment advice.